Pediatric Neurology · Developmental and Epileptic Encephalopathy

The Science of DEE: Why Your Child's Mutation Matters

At a Glance

In Developmental and Epileptic Encephalopathy (DEE), genetic mutations act like stuck switches in the brain. Understanding if your child's mutation is 'Gain-of-Function' (overactive) or 'Loss-of-Function' (underactive) is critical for doctors to choose safe, targeted precision treatments.

The brain functions like a complex electrical circuit. For a child with Developmental and Epileptic Encephalopathy (DEE), the “wiring” or the “switches” in this circuit have a genetic instruction that changes how they work ^[1]. Understanding whether a switch is “stuck on” or “stuck off” is the key to precision medicine—the practice of choosing treatments based on your child’s specific genetic code ^[2].

The Role of Ion Channels: The Brain’s Switches

Most DEEs involve ion channels, which are microscopic gates on brain cells (neurons) that let salt and minerals like sodium (SCN genes) or potassium (KCN genes) flow in and out. This flow creates the electrical signals the brain uses to think and move ^[3]^[4].

Sodium Channels (SCN1A, SCN2A, SCN8A): These usually act like the “gas pedal,” helping brain cells fire ^[5]^[6].
Potassium Channels (KCNQ2): These usually act like the “brakes,” helping brain cells reset and quiet down after firing ^[7]^[8].

Gain-of-Function vs. Loss-of-Function

The most critical distinction for a parent to understand is the “direction” of the mutation. This determines which medications are safe and which are dangerous.

1. Gain-of-Function (GoF): The “Stuck On” Switch

In a Gain-of-Function mutation, the channel works too much or stays open too long.

The Result: The brain becomes hyper-active because the “gas pedal” is floored or the “brakes” are broken.
Example (SCN2A or SCN8A GoF): These children often have seizures very early, within the first days of life ^[9]^[6].
Treatment Strategy: Doctors often use sodium channel blockers (like carbamazepine or phenytoin) to physically plug the overactive channels ^[5]^[10].

2. Loss-of-Function (LoF): The “Stuck Off” Switch

In a Loss-of-Function mutation, the channel doesn’t work well enough.

The Result: This is often more complex. For example, in Dravet Syndrome (SCN1A LoF), the “gas pedal” is broken on the brain’s quieting cells. Without those quiet cells working, the rest of the brain runs wild ^[11]^[12].
DANGER: In SCN1A LoF (Dravet Syndrome), using sodium channel blockers can be harmful because they further weaken the already-struggling quiet cells, making seizures much worse ^[11].

Non-Channel Genes: The Logistics Managers

Not all DEEs are caused by channel “switches.” Some genes manage the “logistics” of the brain cell.

STXBP1: Think of this gene as the “loading dock manager.” It helps brain cells release chemicals (neurotransmitters) to talk to one another ^[13]. When it’s mutated, the cells can’t release these signals properly, leading to seizures and significant movement challenges ^[14]^[15].
CDKL5: This gene acts like a “construction foreman,” organizing the structure and strength of the connections (synapses) between brain cells ^[16]. A lack of CDKL5 disrupts how the brain organizes its circuits, leading to early-onset seizures and vision issues ^[17]^[18].

Summary Table: Genetic Mechanisms

Gene	Primary Job	Mutation Type	Typical Treatment Approach
SCN1A	Quieting the brain	Loss (LoF)	Avoid sodium channel blockers ^[11].
SCN2A	Firing the brain	Gain (GoF)	Often responds to sodium channel blockers ^[5].
KCNQ2	The brain’s “brakes”	Loss (LoF)	Precision “brake-boosters” (Kv7 openers) ^[19].
STXBP1	Releasing signals	Loss (LoF)	Anti-seizure meds + emerging “chaperone” therapies ^[20].

Knowing your child’s specific variant and whether it is GoF or LoF is the most powerful piece of information you can have when discussing new treatments with your medical team ^[2]^[21].

Return to Home Page

Common questions in this guide

What is the difference between Gain-of-Function and Loss-of-Function mutations in DEE?

A gain-of-function mutation means a brain cell channel works too much, acting like a stuck gas pedal. A loss-of-function mutation means the channel doesn't work well enough, acting like broken brakes. Both scenarios can lead to hyperactive electrical signals and seizures.

Why are sodium channel blockers harmful for children with Dravet Syndrome (SCN1A)?

In Dravet Syndrome, the SCN1A loss-of-function mutation weakens the brain's quieting cells. Giving sodium channel blockers further weakens these already-struggling cells, which can make a child's seizures significantly worse.

How do KCNQ2 gene mutations affect the brain?

The KCNQ2 gene controls potassium channels that act like brakes, helping brain cells quiet down after firing. A loss-of-function mutation in this gene removes these brakes, leading to seizures that may require specific precision medicines to treat.

Does the STXBP1 mutation affect brain cell channels?

No, STXBP1 does not control ion channels. Instead, it acts like a manager that helps brain cells release chemical signals to communicate with each other. Mutations in STXBP1 disrupt this communication, leading to seizures and movement challenges.

What does precision medicine mean for DEE?

Precision medicine involves choosing specific treatments based on your child's exact genetic mutation. By knowing whether a brain switch is stuck open or closed, doctors can select medications that directly target the underlying biological problem.

Curated prompts to bring to your next appointment.

1.Does my child's specific genetic variant lead to a 'Gain-of-Function' or 'Loss-of-Function' change in their brain cells?
2.Given this mutation, are 'sodium channel blockers' (like carbamazepine) likely to help or could they potentially make my child's seizures worse?
3.Is my child's seizure onset (e.g., neonatal vs. infantile) consistent with what we typically see for this specific gene mutation?
4.Are there precision medicines, such as Kv7 channel openers for KCNQ2 or chemical chaperones for STXBP1, that we should consider?
5.How does this mutation affect brain functions beyond seizures, such as movement, sleep, or communication?

Tap a prompt to share your answer — we'll use it plus this page's context to start a tailored conversation.

References (21)

1
Developmental and epileptic encephalopathies: what we do and do not know.
Specchio N, Curatolo P
Brain : a journal of neurology 2021; (144(1)):32-43 doi:10.1093/brain/awaa371.
PMID: 33279965
2
Targeted gene panel sequencing in early infantile onset developmental and epileptic encephalopathy.
Na JH, Shin S, Yang D, et al.
Brain & development 2020; (42(6)):438-448 doi:10.1016/j.braindev.2020.02.004.
PMID: 32139178
3
Epilepsy-Related Voltage-Gated Sodium Channelopathies: A Review.
Menezes LFS, Sabiá Júnior EF, Tibery DV, et al.
Frontiers in pharmacology 2020; (11()):1276 doi:10.3389/fphar.2020.01276.
PMID: 33013363
4
Abnormalities in the functional activity of neural networks in a human iPSC model of Dravet syndrome.
Mzezewa R, Hyvärinen T, Kulta O, et al.
Neuroscience research 2025; (220()):104958 doi:10.1016/j.neures.2025.104958.
PMID: 40976436
5
Genetic and phenotypic heterogeneity suggest therapeutic implications in SCN2A-related disorders.
Wolff M, Johannesen KM, Hedrich UBS, et al.
Brain : a journal of neurology 2017; (140(5)):1316-1336 doi:10.1093/brain/awx054.
PMID: 28379373
6
Genotype-phenotype correlations in SCN8A-related epilepsy: a cohort study of Chinese children in southern China.
Peng BW, Tian Y, Chen L, et al.
Brain : a journal of neurology 2022; (145(4)):e24-e27 doi:10.1093/brain/awac038.
PMID: 35230384
7
A de novo KCNQ2 Gene Mutation Associated With Non-familial Early Onset Seizures: Case Report and Revision of Literature Data.
Laccetta G, Fiori S, Giampietri M, et al.
Frontiers in pediatrics 2019; (7()):348 doi:10.3389/fped.2019.00348.
PMID: 31552204
8
Diagnostic Approach to Genetic Causes of Early-Onset Epileptic Encephalopathy.
Gürsoy S, Erçal D
Journal of child neurology 2016; (31(4)):523-32 doi:10.1177/0883073815599262.
PMID: 26271793
9
Efficacy of sodium channel blockers in SCN2A early infantile epileptic encephalopathy.
Dilena R, Striano P, Gennaro E, et al.
Brain & development 2017; (39(4)):345-348 doi:10.1016/j.braindev.2016.10.015.
PMID: 27876397
10
SCN8A Encephalopathy: Case Report and Literature Review.
Fan HC, Lee HF, Chi CS
Neurology international 2021; (13(2)):143-150 doi:10.3390/neurolint13020014.
PMID: 33915942
11
SCN1A/NaV 1.1 channelopathies: Mechanisms in expression systems, animal models, and human iPSC models.
Mantegazza M, Broccoli V
Epilepsia 2019; (60 Suppl 3()):S25-S38 doi:10.1111/epi.14700.
PMID: 31904127
12
A deleterious Nav1.1 mutation selectively impairs telencephalic inhibitory neurons derived from Dravet Syndrome patients.
Sun Y, Paşca SP, Portmann T, et al.
eLife 2016; (5()).
PMID: 27458797
13
Heterozygous STXBP1 Mutations Associated With Ohtahara Syndrome: Two Littles Make a Lot.
Nieto-Estévez V, Hsieh J
Epilepsy currents 2016; (16(5)):330-332 doi:10.5698/1535-7511-16.5.330.
PMID: 27799865
14
Reduced Protein Stability of 11 Pathogenic Missense STXBP1/MUNC18-1 Variants and Improved Disease Prediction.
André T, van Berkel AA, Singh G, et al.
Biological psychiatry 2024; (96(2)):125-136 doi:10.1016/j.biopsych.2024.03.007.
PMID: 38490366
15
An Atypical, Staged Cell Death Pathway Induced by Depletion of SNARE-Proteins MUNC18-1 or Syntaxin-1.
Feringa FM, van Berkel AA, Nair A, Verhage M
The Journal of neuroscience : the official journal of the Society for Neuroscience 2023; (43(3)):347-358 doi:10.1523/JNEUROSCI.0611-22.2022.
PMID: 36517239
16
CDKL5 modulates the plasticity of excitatory synapses via liquid-liquid phase separation.
Li M, Zhu Z, Li D, et al.
Proceedings of the National Academy of Sciences of the United States of America 2026; (123(8)):e2511123123 doi:10.1073/pnas.2511123123.
PMID: 41706882
17
Rett Syndrome and CDKL5 Deficiency Disorder: From Bench to Clinic.
Kadam SD, Sullivan BJ, Goyal A, et al.
International journal of molecular sciences 2019; (20(20)) doi:10.3390/ijms20205098.
PMID: 31618813
18
Dendritic Spine Instability in a Mouse Model of CDKL5 Disorder Is Rescued by Insulin-like Growth Factor 1.
Della Sala G, Putignano E, Chelini G, et al.
Biological psychiatry 2016; (80(4)):302-311 doi:10.1016/j.biopsych.2015.08.028.
PMID: 26452614
19
Phenotypic and functional assessment of two novel KCNQ2 gain-of-function variants Y141N and G239S and effects of amitriptyline treatment.
Bayat A, Iavarone S, Miceli F, et al.
Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics 2024; (21(1)):e00296 doi:10.1016/j.neurot.2023.10.006.
PMID: 38241158
20
Phenylbutyrate for monogenetic epilepsy: Literature review.
Stone A, Burré J, Wayland N, Grinspan ZM
Epilepsy research 2025; (217()):107621 doi:10.1016/j.eplepsyres.2025.107621.
PMID: 40633241
21
SCN2A channelopathies: Mechanisms and models.
Hedrich UBS, Lauxmann S, Lerche H
Epilepsia 2019; (60 Suppl 3()):S68-S76 doi:10.1111/epi.14731.
PMID: 31904120

This page explains the genetics of Developmental and Epileptic Encephalopathy for educational purposes. Always consult your pediatric neurologist or geneticist to interpret your child's specific genetic variant and appropriate treatment plan.

Get notified when new evidence is published on Genetic developmental and epileptic encephalopathy.

We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.

Guide Contents